金城医药(300233) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥931,696,552.76, representing a 12.32% increase compared to ¥829,526,542.00 in the same period last year[5] - Net profit attributable to shareholders increased by 65.43% to ¥82,971,349.76 from ¥50,154,655.33 year-on-year[5] - Basic and diluted earnings per share increased by 69.23% to ¥0.22, compared to ¥0.13 in the same period last year[5] - The net profit for Q1 2024 reached CNY 89,158,928.05, representing a significant increase of 62.5% from CNY 54,879,668.97 in Q1 2023[23] - The company's basic and diluted earnings per share for Q1 2024 were both CNY 0.22, compared to CNY 0.13 in the same period last year, marking a 69.2% increase[24] Cash Flow - The net cash flow from operating activities rose by 54.94% to ¥41,373,196.64, up from ¥26,703,337.29 in the previous year[11] - The net cash flow from operating activities for the current period is ¥41,373,196.64, an increase of 55% compared to ¥26,703,337.29 in the previous period[27] - Total cash inflow from operating activities is ¥908,762,226.03, up from ¥772,155,286.99, reflecting a growth of approximately 17.7%[27] - Cash outflow from operating activities increased to ¥867,389,029.39 from ¥745,451,949.70, representing a rise of about 16.4%[27] - The net cash flow from financing activities decreased by 68.97% to ¥25,751,266.86, down from ¥82,984,423.07 in the previous year, primarily due to stock repurchase expenditures[11] - The net cash flow from financing activities is ¥25,751,266.86, down from ¥82,984,423.07, showing a decrease of approximately 69%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,900,503,765.77, a slight decrease of 0.26% from ¥5,916,079,328.81 at the end of the previous year[5] - The total liabilities decreased to CNY 2,081,569,716.22 from CNY 2,135,019,888.07, indicating a reduction of 2.5% year-over-year[21] - The company experienced an 86.88% increase in current liabilities due within one year, totaling ¥205,490,777.68, compared to ¥109,957,297.08 in the previous year[9] Research and Development - Research and development expenses increased by 32.32% to ¥37,715,121.84, up from ¥28,502,407.61 in the previous year[10] - Research and development expenses for Q1 2024 were CNY 37,715,121.84, up from CNY 28,502,407.61 in Q1 2023, indicating a 32.3% increase[22] Shareholder Information - The largest shareholder, Zibo Jincheng Industrial Investment Co., holds 20.46% of the shares, amounting to 78,552,154 shares, with 33,556,400 shares pledged[14] - The second-largest shareholder, the National Social Security Fund, holds 2.94% of the shares, totaling 11,300,000 shares[14] - The company’s repurchase account holds 4,543,000 shares, accounting for 1.18% of the total share capital[14] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[14] Inventory and Receivables - Accounts receivable decreased to ¥560,843,824.49 from ¥608,006,392.29, indicating a reduction of about 7.8%[19] - Inventory increased to ¥533,067,145.66 from ¥501,281,573.25, representing a rise of approximately 6.3%[19] Financial Assets - The company’s financial assets include derivative financial assets valued at ¥223,563.77, a significant increase from ¥20,507.24[19] - The company’s prepayments increased to ¥35,633,225.09 from ¥30,701,553.69, reflecting a growth of approximately 16.0%[19] Overall Financial Health - The weighted average return on equity improved to 2.22%, up from 1.38% in the previous year[5] - The total equity attributable to shareholders of the parent company increased to CNY 3,744,616,592.63 from CNY 3,714,133,643.74, reflecting a growth of 0.8%[21] - The company reported a significant increase in contract liabilities by 41.87% to ¥46,446,623.27, compared to ¥32,738,866.37 in the previous year[9]